| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US11351149 | PFIZER | Nitrile-containing antiviral compounds |
Aug, 2041
(17 years from now) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11541034 | PFIZER | Nitrile-containing antiviral compounds |
Oct, 2041
(17 years from now) | |
Paxlovid (Copackaged) is owned by Pfizer.
Paxlovid (Copackaged) contains Nirmatrelvir; Ritonavir.
Paxlovid (Copackaged) has a total of 2 drug patents out of which 0 drug patents have expired.
Paxlovid (Copackaged) was authorised for market use on 25 May, 2023.
Paxlovid (Copackaged) is available in tablet;oral dosage forms.
Paxlovid (Copackaged) can be used as treatment of mild-to-moderate coronavirus disease 2019 (covid-19) in adults who are at high risk for progression to severe covid-19, including hospitalization or death.
Drug patent challenges can be filed against Paxlovid (Copackaged) from 26 May, 2027.
The generics of Paxlovid (Copackaged) are possible to be released after 31 October, 2041.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | May 25, 2028 |
Drugs and Companies using NIRMATRELVIR; RITONAVIR ingredient
NCE-1 date: 26 May, 2027
Market Authorisation Date: 25 May, 2023
Treatment: Treatment of mild-to-moderate coronavirus disease 2019 (covid-19) in adults who are at high risk for progression to severe covid-19, including hospitalization or death
Dosage: TABLET;ORAL
PAXLOVID (COPACKAGED) family patents
